Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.

Altimmune, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

AI-BASED DIGITAL PATHOLOGY ANALYSIS PROVIDES HIGH-RESOLUTION QUANTIFICATION OF HEPATIC FIBROSIS AND OBJECTIVE MEASUREMENT OF FIBROSIS IMPROVEMENT

ALTIMMUNE PRESENTS AI-BASED ANALYSIS OF LIVER FIBROSIS REDUCTION FROM IMPACT PHASE 2B TRIAL OF PEMVIDUTIDE IN MASH IN LATE-BREAKING POSTER AT AASLD THE LIVER MEETING 2025

48-WEEK DATA FROM PHASE 2B IMPACT TRIAL OF PEMVIDUTIDE IN MASH EXPECTED BEFORE YEAR END END-OF-PHASE 2 MEETING WITH FDA FOR MASH PROGRAM SCHEDULED IN FOURTH QUARTER EXECUTIVE LEADERSHIP STRENGTHENED WITH APPOINTMENTS OF CHIEF MEDICAL OFFICER, CHIEF COMMERCIAL OFFICER, AND CHIEF LEGAL OFFICER CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS OF $211 MILLION AS OF SEPTEMBER 30, 2025 WEBCAST TO BE HELD TODAY, NOVEMBER 6, 2025, AT 8:30 A.M. ET GAITHERSBURG, MD.

ALTIMMUNE ANNOUNCES THIRD QUARTER 2025 FINANCIAL RESULTS AND BUSINESS UPDATES

GAITHERSBURG, MD., NOV. 05, 2025 (GLOBE NEWSWIRE) -- ALTIMMUNE, INC. (NASDAQ: ALT), A LATE CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING NOVEL PEPTIDE-BASED THERAPEUTICS FOR LIVER AND CARDIOMETABOLIC DISEASES, TODAY ANNOUNCED THAT MEMBERS OF THE COMPANY'S MANAGEMENT TEAM WILL PARTICIPATE AND BE AVAILABLE FOR ONE-ON-ONE MEETINGS AT THE FOLLOWING INVESTOR CONFERENCES: STIFEL 2025 HEALTHCARE CONFERENCE WEDNESDAY, NOVEMBER 12, 2025 FIRESIDE CHAT AT 10:00 A.M.

ALTIMMUNE TO PARTICIPATE IN TWO UPCOMING INVESTOR CONFERENCES

ENROLLMENT COMPLETED AHEAD OF SCHEDULE, UNDERSCORING STRONG INTEREST FROM PATIENT COMMUNITY IN A POTENTIAL NEW THERAPEUTIC OPTION ON TRACK TO COMPLETE THE 24-WEEK TREATMENT PERIOD AND ANNOUNCE TOPLINE RESULTS IN 2026 GAITHERSBURG, MD., NOV. 03, 2025 (GLOBE NEWSWIRE) -- ALTIMMUNE, INC. (NASDAQ: ALT), A LATE CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING NOVEL PEPTIDE-BASED THERAPEUTICS FOR LIVER AND CARDIOMETABOLIC DISEASES, TODAY ANNOUNCED THE COMPLETION OF PATIENT ENROLLMENT IN RECLAIM, A PHASE 2 CLINICAL TRIAL EVALUATING PEMVIDUTIDE IN ADULTS WITH ALCOHOL USE DISORDER (AUD).

ALTIMMUNE ANNOUNCES EARLY COMPLETION OF ENROLLMENT IN RECLAIM PHASE 2 TRIAL EVALUATING PEMVIDUTIDE IN ALCOHOL USE DISORDER

GAITHERSBURG, MD., OCT. 30, 2025 (GLOBE NEWSWIRE) -- ALTIMMUNE, INC. (NASDAQ: ALT), A LATE CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING NOVEL PEPTIDE-BASED THERAPEUTICS FOR LIVER AND CARDIOMETABOLIC DISEASES, TODAY ANNOUNCED THAT IT WILL REPORT ITS THIRD QUARTER 2025 FINANCIAL RESULTS ON THURSDAY, NOVEMBER 6, 2025.

ALTIMMUNE TO REPORT THIRD QUARTER 2025 FINANCIAL RESULTS AND PROVIDE BUSINESS UPDATE ON NOVEMBER 6, 2025

ORAL PRESENTATION TO HIGHLIGHT 24-WEEK EFFICACY AND SAFETY DATA POSTER TO FEATURE RESULTS OF AI-BASED ANALYSES OF LIVER FIBROSIS REDUCTION GAITHERSBURG, MD., OCT. 20, 2025 (GLOBE NEWSWIRE) -- ALTIMMUNE, INC. (NASDAQ: ALT), A LATE CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING NOVEL PEPTIDE-BASED THERAPEUTICS FOR LIVER AND CARDIOMETABOLIC DISEASES, TODAY ANNOUNCED THAT 24-WEEK DATA FROM ITS PHASE 2B IMPACT TRIAL OF PEMVIDUTIDE IN METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH) WILL BE PRESENTED IN LATE-BREAKING ORAL AND POSTER PRESENTATIONS AT THE LIVER MEETING 2025, HOSTED BY THE AMERICAN ASSOCIATION FOR THE STUDY OF LIVER DISEASES (AASLD) IN WASHINGTON, D.C.

ALTIMMUNE TO PRESENT PHASE 2B IMPACT DATA ON PEMVIDUTIDE IN MASH IN LATE-BREAKING ORAL PODIUM PRESENTATION AND LATE-BREAKING POSTER AT AASLD THE LIVER MEETING 2025

LAS VEGAS--(BUSINESS WIRE)--ALT5 SIGMA CORPORATION (THE "COMPANY," "OUR" OR "ALT5") (NASDAQ: ALTS) (FRA:5AR1), THE $WLFI DIGITAL ASSET TREASURY COMPANY, TODAY NOTED CONTINUED WORLD LIBERTY FINANCIAL (WLFI) AND $WLFI ADVANCEMENTS THAT ARE EXPECTED TO FURTHER SUPPORT THE COMPANY'S DIGITAL ASSET TREASURY STRATEGY. $WLFI STRATEGIC ASIAN MARKET EXPANSION AS PART OF ITS GEOGRAPHIC EXPANSION STRATEGY, WORLD LIBERTY FINANCIAL HAS SIGNED A MEMORANDUM OF UNDERSTANDING WITH SOUTH KOREA'S BITHUMB, ONE OF A.

ALT5 SIGMA TREASURY STRATEGY SUPPORTED BY WORLD LIBERTY FINANCIAL'S INTERNATIONAL EXPANSION AND $WFLI TOKEN BURN

LAS VEGAS--(BUSINESS WIRE)--ALT5 SIGMA CORPORATION (THE "COMPANY," "OUR" OR "ALT5") (NASDAQ: ALTS) (FRA:5AR1), THE $WLFI DIGITAL ASSET TREASURY COMPANY, TODAY ISSUED A LETTER TO ITS STOCKHOLDERS: DEAR STOCKHOLDERS, YOU SHOULD HAVE RECEIVED BY MAIL A COPY OF THE PROXY MATERIALS FOR THE OCTOBER 10, 2025, SPECIAL MEETING OF THE STOCKHOLDERS OF ALT5 SIGMA CORPORATION. THE PROXY MATERIALS CONTAIN INSTRUCTIONS ON HOW TO VOTE YOUR SHARES, INCLUDING THE CONTROL NUMBER ASSOCIATED WITH YOUR PROXY CARD. I.

ALT5 SIGMA ISSUES LETTER TO STOCKHOLDERS

LAS VEGAS--(BUSINESS WIRE)--ALT5 SIGMA CORPORATION (THE "COMPANY," "OUR" OR "ALT5") (NASDAQ: ALTS) (FRA:5AR1), THE $WLFI DIGITAL ASSET TREASURY COMPANY, TODAY ANNOUNCED THAT IT WILL PARTICIPATE IN A.G.P. (ALLIANCE GLOBAL PARTNERS) DIGITAL ASSETS & TECHNOLOGY (DAT) SHOWCASE ON OCTOBER 8, 2025, AT 9:00 A.M. ET. THE PRESENTATION WILL FEATURE JONATHAN HUGH, CHIEF FINANCIAL OFFICER OF ALT5 SIGMA, ALONGSIDE ZAK FOLKMAN, CO-FOUNDER OF WORLD LIBERTY FINANCIAL, AND MATT MORGAN, ADVISOR TO WORLD LIBE.

ALT5 SIGMA AND WORLD LIBERTY FINANCIAL TO PRESENT AT A.G.P.'S DIGITAL ASSETS & TECHNOLOGY SHOWCASE

NEW YORK--(BUSINESS WIRE)-- #CLASSACTION--FARUQI & FARUQI, LLP, A LEADING NATIONAL SECURITIES LAW FIRM, IS INVESTIGATING POTENTIAL CLAIMS AGAINST ALTIMMUNE, INC. (ALTIMMUNE OR THE COMPANY) (NASDAQ: ALT) AND REMINDS INVESTORS OF THE OCTOBER 6, 2025 DEADLINE TO SEEK THE ROLE OF LEAD PLAINTIFF IN A FEDERAL SECURITIES CLASS ACTION THAT HAS BEEN FILED AGAINST THE COMPANY. FARUQI & FARUQI IS A LEADING NATIONAL SECURITIES LAW FIRM WITH OFFICES IN NEW YORK, PENNSYLVANIA, CALIFORNIA AND GEORGIA. THE FIRM H.

FINAL DEADLINE ALERT: FARUQI & FARUQI, LLP INVESTIGATES CLAIMS ON BEHALF OF INVESTORS OF ALTIMMUNE

ALTIMMUNE ALLEGEDLY MISLED INVESTORS ON PEMVIDUTIDE'S MASH TRIAL, WHICH FAILED ITS KEY FIBROSIS ENDPOINT, CAUSING SHARES TO PLUNGE 53% ON JUNE 26, 2025.

ALTIMMUNE FINAL DEADLINE REMINDER: BRAGAR EAGEL & SQUIRE, P.C. URGES INVESTORS TO CONTACT THE FIRM REGARDING THE OCTOBER 6TH DEADLINE

LAS VEGAS--(BUSINESS WIRE)--ALT5 SIGMA CORPORATION (THE "COMPANY," "OUR" OR "ALT5") (NASDAQ: ALTS) (FRA:5AR1), THE $WLFI DIGITAL ASSET TREASURY COMPANY, TODAY HIGHLIGHTED RECENT ADVANCEMENTS IN THE $WLFI ECOSYSTEM THAT THE COMPANY BELIEVES WILL SUBSTANTIALLY STRENGTHEN THE $WLFI TOKEN, THE ASSET ON WHICH THE COMPANY'S DIGITAL ASSET TREASURY STRATEGY IS BASED  THE LAUNCH OF $WLFI ON ROBINHOOD, AND WORLD LIBERTY FINANCIAL'S PLANNED INTRODUCTION OF A WLFI-BRANDED DEBIT CARD, WHICH WOULD ALLOW USD.

ALT5 SIGMA TREASURY STRATEGY STRENGTHENED BY ACCELERATING $WLFI ADOPTION DRIVEN BY ROBINHOOD LAUNCH AND POTENTIAL APPLE PAY INTEGRATION WITH USD1

FARUQI & FARUQI, LLP SECURITIES LITIGATION PARTNER JAMES (JOSH) WILSON ENCOURAGES INVESTORS WHO SUFFERED LOSSES IN ALTIMMUNE TO CONTACT HIM DIRECTLY TO DISCUSS THEIR OPTIONS

ALT INVESTOR NOTICE: FARUQI & FARUQI, LLP INVESTIGATES CLAIMS ON BEHALF OF INVESTORS OF ALTIMMUNE

FARUQI & FARUQI, LLP SECURITIES LITIGATION PARTNER JAMES (JOSH) WILSON ENCOURAGES INVESTORS WHO SUFFERED LOSSES IN ALTIMMUNE TO CONTACT HIM DIRECTLY TO DISCUSS THEIR OPTIONS IF YOU PURCHASED OR ACQUIRED SECURITIES IN ALTIMMUNE BETWEEN AUGUST 10, 2023 AND JUNE 25, 2025 AND WOULD LIKE TO DISCUSS YOUR LEGAL RIGHTS, CALL FARUQI & FARUQI PARTNER JOSH WILSON DIRECTLY AT 877-247-4292 OR 212-983-9330 (EXT. 1310). [YOU MAY ALSO CLICK HERE FOR ADDITIONAL INFORMATION] NEW YORK , OCT. 3, 2025 /PRNEWSWIRE/ -- FARUQI & FARUQI, LLP, A LEADING NATIONAL SECURITIES LAW FIRM, IS INVESTIGATING POTENTIAL CLAIMS AGAINST ALTIMMUNE, INC. ("ALTIMMUNE" OR THE "COMPANY") (NASDAQ: ALT) AND REMINDS INVESTORS OF THE OCTOBER 6, 2025 DEADLINE TO SEEK THE ROLE OF LEAD PLAINTIFF IN A FEDERAL SECURITIES CLASS ACTION THAT HAS BEEN FILED AGAINST THE COMPANY.

SHAREHOLDER REMINDER: FARUQI & FARUQI, LLP INVESTIGATES CLAIMS ON BEHALF OF INVESTORS OF ALTIMMUNE

NEW YORK , OCT. 1, 2025 /PRNEWSWIRE/ -- LEVI & KORSINSKY, LLP NOTIFIES INVESTORS IN ALTIMMUNE, INC. ("ALTIMMUNE" OR THE "COMPANY") (NASDAQ: ALT) OF A CLASS ACTION SECURITIES LAWSUIT. CLASS DEFINITION: THE LAWSUIT SEEKS TO RECOVER LOSSES ON BEHALF OF ALTIMMUNE INVESTORS WHO WERE ADVERSELY AFFECTED BY ALLEGED SECURITIES FRAUD BETWEEN AUGUST 10, 2023 AND JUNE 25, 2025.

INVESTORS IN ALTIMMUNE, INC. SHOULD CONTACT LEVI & KORSINSKY BEFORE OCTOBER 6, 2025 TO DISCUSS YOUR RIGHTS - ALT

LOS ANGELES--(BUSINESS WIRE)--ALTIMMUNE, INC. SUED FOR SECURITIES LAW VIOLATIONS - CONTACT THE DJS LAW GROUP TO DISCUSS YOUR RIGHTS  ALT.

ALTIMMUNE, INC. SUED FOR SECURITIES LAW VIOLATIONS - CONTACT THE DJS LAW GROUP TO DISCUSS YOUR RIGHTS  ALT

INVESTOR DEADLINE APPROACHING: FARUQI & FARUQI, LLP INVESTIGATES CLAIMS ON BEHALF OF INVESTORS OF ALTIMMUNE

SEASONED CLINICAL LEADER TO OVERSEE PHASE 3 DEVELOPMENT OF PEMVIDUTIDE IN MASH DR. ARBET-ENGELS HAS LED LATE-STAGE DEVELOPMENT, REGULATORY APPROVALS AND COMMERCIAL LAUNCHES FOR MULTIPLE SUCCESSFUL FRANCHISES GAITHERSBURG, MD., SEPT. 29, 2025 (GLOBE NEWSWIRE) -- ALTIMMUNE, INC. (NASDAQ: ALT), A LATE CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING NOVEL PEPTIDE-BASED THERAPEUTICS FOR LIVER AND CARDIOMETABOLIC DISEASES, TODAY ANNOUNCED THE APPOINTMENT OF CHRISTOPHE ARBET-ENGELS, MD, PHD AS CHIEF MEDICAL OFFICER, EFFECTIVE OCTOBER 1, 2025.

ALTIMMUNE APPOINTS INDUSTRY VETERAN CHRISTOPHE ARBET-ENGELS, M.D., PHD AS CHIEF MEDICAL OFFICER TO DRIVE NEXT PHASE OF CLINICAL DEVELOPMENT OF PEMVIDUTIDE

NEW YORK , SEPT. 25, 2025 /PRNEWSWIRE/ -- THE GROSS LAW FIRM ISSUES THE FOLLOWING NOTICE TO SHAREHOLDERS OFALTIMMUNE, INC. (NASDAQ: ALT).

INVESTORS IN ALTIMMUNE, INC. SHOULD CONTACT THE GROSS LAW FIRM BEFORE OCTOBER 6, 2025 TO DISCUSS YOUR RIGHTS - ALT

GAITHERSBURG, MD., SEPT. 23, 2025 (GLOBE NEWSWIRE) -- ALTIMMUNE, INC. (NASDAQ: ALT), A LATE CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING NOVEL PEPTIDE-BASED THERAPEUTICS FOR LIVER AND CARDIOMETABOLIC DISEASES, TODAY ANNOUNCED THAT MEMBERS OF THE COMPANY'S MANAGEMENT TEAM WILL PARTICIPATE AND BE AVAILABLE FOR 1X1 MEETINGS AT THE FOLLOWING INVESTOR CONFERENCES:

FARUQI & FARUQI, LLP SECURITIES LITIGATION PARTNER JAMES (JOSH) WILSON ENCOURAGES INVESTORS WHO SUFFERED LOSSES EXCEEDING $75,000 IN ALTIMMUNE TO CONTACT HIM DIRECTLY TO DISCUSS THEIR OPTIONS

SHAREHOLDER NOTICE: FARUQI & FARUQI, LLP INVESTIGATES CLAIMS ON BEHALF OF INVESTORS OF ALTIMMUNE

GAITHERSBURG, MD., SEPT. 15, 2025 (GLOBE NEWSWIRE) -- ALTIMMUNE, INC. (NASDAQ: ALT), A LATE CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING NOVEL PEPTIDE-BASED THERAPEUTICS FOR LIVER AND CARDIOMETABOLIC DISEASES, TODAY ANNOUNCED THE APPOINTMENT OF LINDA M.

ALTIMMUNE APPOINTS ACCOMPLISHED COMMERCIAL EXECUTIVE LINDA M. RICHARDSON AS CHIEF COMMERCIAL OFFICER

FARUQI & FARUQI, LLP SECURITIES LITIGATION PARTNER JAMES (JOSH) WILSON ENCOURAGES INVESTORS WHO SUFFERED LOSSES EXCEEDING $75,000 IN ALTIMMUNE TO CONTACT HIM DIRECTLY TO DISCUSS THEIR OPTIONS IF YOU SUFFERED LOSSES EXCEEDING $75,000 IN ALTIMMUNE BETWEEN AUGUST 10, 2023 AND JUNE 25, 2025 AND WOULD LIKE TO DISCUSS YOUR LEGAL RIGHTS, CALL FARUQI & FARUQI PARTNER JOSH WILSON DIRECTLY AT 877-247-4292 OR 212-983-9330 (EXT. 1310). [YOU MAY ALSO CLICK HERE FOR ADDITIONAL INFORMATION] NEW YORK , SEPT.

NEW YORK, SEPT. 11, 2025 (GLOBE NEWSWIRE) -- LEVI & KORSINSKY, LLP NOTIFIES INVESTORS IN ALTIMMUNE, INC. ("ALTIMMUNE" OR THE "COMPANY") (NASDAQ: ALT) OF A CLASS ACTION SECURITIES LAWSUIT.

SHAREHOLDERS OF ALTIMMUNE, INC. SHOULD CONTACT LEVI & KORSINSKY BEFORE OCTOBER 6, 2025 TO DISCUSS YOUR RIGHTS  ALT

NEW YORK , SEPT. 11, 2025 /PRNEWSWIRE/ -- THE GROSS LAW FIRM ISSUES THE FOLLOWING NOTICE TO SHAREHOLDERS OF ALTIMMUNE, INC. (NASDAQ: ALT).

ALTIMMUNE, INC. SUED FOR SECURITIES LAW VIOLATIONS - INVESTORS SHOULD CONTACT THE GROSS LAW FIRM BEFORE OCTOBER 6, 2025 TO DISCUSS YOUR RIGHTS - ALT

NEW YORK , SEPT. 9, 2025 /PRNEWSWIRE/ -- LEVI & KORSINSKY, LLP NOTIFIES INVESTORS IN ALTIMMUNE, INC. ("ALTIMMUNE" OR THE "COMPANY") (NASDAQ: ALT) OF A CLASS ACTION SECURITIES LAWSUIT.

ALTIMMUNE, INC. SUED FOR SECURITIES LAW VIOLATIONS - INVESTORS SHOULD CONTACT LEVI & KORSINSKY FOR MORE INFORMATION - ALT

FARUQI & FARUQI, LLP SECURITIES LITIGATION PARTNER JAMES (JOSH) WILSON ENCOURAGES INVESTORS WHO SUFFERED LOSSES IN ALTIMMUNE TO CONTACT HIM DIRECTLY TO DISCUSS THEIR OPTIONS IF YOU PURCHASED OR ACQUIRED SECURITIES IN ALTIMMUNE BETWEEN AUGUST 10, 2023 AND JUNE 25, 2025 AND WOULD LIKE TO DISCUSS YOUR LEGAL RIGHTS, CALL FARUQI & FARUQI PARTNER JOSH WILSON DIRECTLY AT 877-247-4292 OR 212-983-9330 (EXT. 1310). [YOU MAY ALSO CLICK HERE FOR ADDITIONAL INFORMATION] NEW YORK , SEPT.

LAS VEGAS--(BUSINESS WIRE)--ALT5 SIGMA CORPORATION (THE COMPANY, OUR OR ALT5) (NASDAQ: ALTS) (FRA:5AR1), A FINTECH SPECIALIZING IN TURNKEY, CRYPTO-RELATED SOLUTIONS FOR INSTITUTIONS AND MERCHANTS, TODAY ANNOUNCED AN UPDATE TO ITS $WLFI HOLDINGS. AS OF THIS RELEASE, ALT5 HOLDS APPROXIMATELY 7.28 BILLION $WLFI TOKENS. IN ADDITION, THE COMPANY IS HIGHLIGHTING THAT THE $WLFI TOKEN  THE FOUNDATIONAL DIGITAL ASSET UNDERPINNING ITS DIGITAL ASSET TREASURY STRATEGY  IS CURRENTLY AVAILABLE FOR TR.

Altimmune, Inc.

ALT

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Altimmune, Inc.

ALT.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

ALT